A Phase III Clinical Study Comparing the Efficacy and Safety of Once-weekly GZR4 Versus Once-daily Insulin Glargine U100 in Combination with Insulin Aspart (with or Without Non-Insulin Antidiabetic Agents) in Subjects with Type 2 Diabetes Mellitus (T2DM) Treated with Basal+Prandial Insulin Treatment
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs Insulin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Gan&Lee Pharmaceuticals
- 16 Jan 2025 New trial record